Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Development of herceptin.

Carter P, Fendly BM, Lewis GD, Sliwkowski MX.

Breast Dis. 2000;11:103-11. No abstract available.

PMID:
15687596
2.

Novel non-isotopic method for the localization of receptors in tissue sections.

Desnoyers L, Simonette RA, Vandlen RL, Fendly BM.

J Histochem Cytochem. 2001 Dec;49(12):1509-18.

PMID:
11724898
3.

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.

Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. Review.

PMID:
10482195
4.

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.

Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ.

Cancer Immunol Immunother. 1999 Feb;47(6):337-42.

PMID:
10203064
5.

Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites.

Pearce KH Jr, Potts BJ, Presta LG, Bald LN, Fendly BM, Wells JA.

J Biol Chem. 1997 Aug 15;272(33):20595-602.

6.

Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX.

Cancer Res. 1996 Mar 15;56(6):1457-65.

7.
8.
9.

Activation of TNF-R1 receptor in the presence of copper kills TNF resistant CEM leukemic T cells.

Wada HG, Fok KS, Fendly BM, Chiang NY, Sussman HH.

J Cell Physiol. 1994 Dec;161(3):597-605.

PMID:
7962141
10.

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.

Oncogene. 1994 Jul;9(7):1829-38.

PMID:
7911565
11.

Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL 3rd.

J Biol Chem. 1994 May 20;269(20):14661-5.

13.

Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor.

Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, Palladino MA Jr.

J Immunol. 1993 Nov 1;151(9):4637-41.

PMID:
8409424
14.

Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW.

J Virol. 1993 Oct;67(10):6179-91.

15.

Humanization of an antibody directed against IgE.

Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM.

J Immunol. 1993 Sep 1;151(5):2623-32.

PMID:
8360482
16.

Development of a specific and sensitive two-site enzyme-linked immunosorbent assay for measurement of inhibin-A in serum.

Baly DL, Allison DE, Krummen LA, Woodruff TK, Soules MR, Chen SA, Fendly BM, Bald LN, Mathers JP, Lucas C.

Endocrinology. 1993 May;132(5):2099-108.

PMID:
8477659
17.

A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, et al.

Mol Cell Biol. 1993 Apr;13(4):2247-57.

18.

Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.

Nakamura GR, Byrn R, Rosenthal K, Porter JP, Hobbs MR, Riddle L, Eastman DJ, Dowbenko D, Gregory T, Fendly BM, et al.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1875-85.

PMID:
1283308
20.

Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation.

Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, Fendly BM, Lipari MT, Goeddel DV.

J Biol Chem. 1992 Oct 15;267(29):21172-8.

21.

High resolution functional analysis of antibody-antigen interactions.

Jin L, Fendly BM, Wells JA.

J Mol Biol. 1992 Aug 5;226(3):851-65.

PMID:
1380563
22.

HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.

Arnaout AH, Dawson PM, Soomro S, Taylor P, Theodorou NA, Feldmann M, Fendly BM, Shepard HM, Shousha S.

J Clin Pathol. 1992 Aug;45(8):726-7.

23.

Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding.

Marsters SA, Frutkin AD, Simpson NJ, Fendly BM, Ashkenazi A.

J Biol Chem. 1992 Mar 25;267(9):5747-50.

25.

Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation.

Pennica D, Kohr WJ, Fendly BM, Shire SJ, Raab HE, Borchardt PE, Lewis M, Goeddel DV.

Biochemistry. 1992 Feb 4;31(4):1134-41.

PMID:
1310420
26.

Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.

Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM.

Growth Regul. 1991 Jun;1(2):72-82.

PMID:
1688187
27.

Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.

Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A, et al.

J Clin Immunol. 1991 May;11(3):117-27. Review.

PMID:
1679763
28.

Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.

Teng MN, Park BH, Koeppen HK, Tracey KJ, Fendly BM, Schreiber H.

Proc Natl Acad Sci U S A. 1991 May 1;88(9):3535-9.

29.

Evidence for an autocrine role of activin B within rat anterior pituitary cultures.

Corrigan AZ, Bilezikjian LM, Carroll RS, Bald LN, Schmelzer CH, Fendly BM, Mason AJ, Chin WW, Schwall RH, Vale W.

Endocrinology. 1991 Mar;128(3):1682-4.

PMID:
1900235
30.

TGF-beta: a possible autocrine immune regulator.

Lucas C, Wallick S, Fendly BM, Figari I, Palladino MA.

Ciba Found Symp. 1991;157:98-108; discussion 108-14.

PMID:
2070686
31.

Generation of antibodies and assays for transforming growth factor beta.

Lucas C, Fendly BM, Mukku VR, Wong WL, Palladino MA.

Methods Enzymol. 1991;198:303-16. No abstract available.

PMID:
1857224
32.

The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.

Fendly BM, Kotts C, Vetterlein D, Lewis GD, Winget M, Carver ME, Watson SR, Sarup J, Saks S, Ullrich A, et al.

J Biol Response Mod. 1990 Oct;9(5):449-55.

PMID:
1979347
33.

Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.

Ashkenazi A, Presta LG, Marsters SA, Camerato TR, Rosenthal KA, Fendly BM, Capon DJ.

Proc Natl Acad Sci U S A. 1990 Sep;87(18):7150-4.

34.

The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA.

Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA.

J Immunol. 1990 Sep 1;145(5):1415-22.

PMID:
2384664
35.

Increase in cyclic AMP levels by relaxin in newborn rhesus monkey uterus cell culture.

Kramer SM, Gibson UE, Fendly BM, Mohler MA, Drolet DW, Johnston PD.

In Vitro Cell Dev Biol. 1990 Jun;26(6):647-56.

PMID:
2162818
36.

Mammalian cell transient expression of tissue factor for the production of antigen.

Paborsky LR, Fendly BM, Fisher KL, Lawn RM, Marks BJ, McCray G, Tate KM, Vehar GA, Gorman CM.

Protein Eng. 1990 May;3(6):547-53.

PMID:
2164668
37.

Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues.

Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A.

Int J Cancer. 1990 Mar 15;45(3):457-61.

PMID:
1968437
38.

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A.

Cancer Res. 1990 Mar 1;50(5):1550-8.

39.

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A.

Mol Cell Biol. 1989 Mar;9(3):1165-72.

40.

Murine monoclonal antibodies defining neutralizing epitopes on tumor necrosis factor.

Fendly BM, Toy KJ, Creasey AA, Vitt CR, Larrick JW, Yamamoto R, Lin LS.

Hybridoma. 1987 Aug;6(4):359-70.

PMID:
2442093
41.

Characterization of murine monoclonal antibodies that recognize neutralizing epitopes on human C5a.

Larrick JW, Wang J, Fendly BM, Chenoweth DE, Kunkel SL, Deinhart T.

Infect Immun. 1987 Aug;55(8):1867-72.

42.

Recombinant tumor necrosis factor causes activation of human granulocytes.

Larrick JW, Graham D, Toy K, Lin LS, Senyk G, Fendly BM.

Blood. 1987 Feb;69(2):640-4.

PMID:
3801673
43.

Species-specific monoclonal antibody to a 43,000-molecular-weight membrane protein of Mycoplasma pneumoniae.

Madsen RD, Saeed FA, Gray O, Fendly BM, Coates SR.

J Clin Microbiol. 1986 Oct;24(4):680-3.

44.

A simplified new method for HLA-DR typing using the TM1 monoclonal antibody.

Grumet FC, Pask SB, Ness DB, Fendly BM, Engleman EG.

Hum Immunol. 1983 Feb;6(2):63-73.

PMID:
6601099
45.

Monoclonal antibody (B27M2) subdividing HLA-B27.

Grumet FC, Fendly BM, Fish L, Foung S, Engleman EG.

Hum Immunol. 1982 Aug;5(1):61-72. No abstract available.

PMID:
6981637
47.

HLA-DR epitope region definition by use of monoclonal antibody probes.

Grumet FC, Charron DJ, Fendly BM, Levy R, Ness DB.

J Immunol. 1980 Dec;125(6):2785-9.

PMID:
6159421

Supplemental Content

Loading ...
Support Center